STSoichi Takiguchi

Soichi Takiguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Soichi Takiguchi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Haruo Iguchi

    Clinical Research Institute, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, Japan

    2 shared publications
  • Akihiro Funakoshi

    Department of Gastroenterology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan

    1 shared publication
  • Akihiro Funakoshi

    Department of Gastroenterology, National Kyushu Cancer Center, Fukuoka, Japan

    1 shared publication
  • Ayako Sekime

    Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakaecho Itabashiku 173-0015, Tokyo, Japan

    1 shared publication
  • Kazuko Inoue

    Clinical Research Institute, National Kyushu Cancer Center, Fukuoka 811-1395, Japan

    1 shared publication
  • Kimihiko Matsusue

    Department of Hygiene Chemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan

    1 shared publication

Latest Publications

  • Open Access

    Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer

    by Soichi Takiguchi, Kazuko Inoue, Kimihiko Matsusue, Masayuki Furukawa, Norihiro Teramoto, Haruo Iguchi

    Peritoneal dissemination is a frequent occurrence in pancreatic cancer, which is associated with a poor prognosis. MET is associated with the progression of pancreatic cancer; therefore, we evaluated the effect of a MET inhibitor, crizotinib, on peritoneal dissemination of pancreatic cancer. Crizotinib inhibited the growth of 8 pancreatic cancer cell lines with the IC50 ranging from 1.4 to 4.3 µM. Invasion of the pancreatic cancer cell line Suit-2, was suppressed in vitro at a concentration of 1.0 µM, which is sufficient for the inhibition of MET phosphorylation. This effect on cell invasion was also recapitulated by the reduction of MET expression in Suit-2 with siRNA. Crizotinib also inhibited RhoA activation in addition to MET phosphorylation. We further evaluated the effect of crizotinib on peritoneal dissemination of pancreatic cancer in vivo. Crizotinib reduced tumor burden and ascites accumulation due to development of peritoneal dissemination after inoculation of Suit-2. Taken together, crizotinib may be a potent drug for treating peritoneal dissemination of pancreatic cancer by inhibiting cancer cell proliferation and invasion, at least in part through the suppression of HGF/MET signaling and RhoA activation.


  • Open Access

    Susceptibility to obesity and gallbladder stasis produced by a protein- and fat-enriched diet in male mice compared with female mice

    by Kyoko Miyasaka, Setsuko Kanai, Minoru Ohta, Ayako Sekime, Saeko Akimoto, Soichi Takiguchi, Akihiro Funakoshi

    The frequency of Japanese subjects over 20 years old with metabolic syndrome is 45.6% in men but just 16.7% in women. The reason why Japanese male subjects are more susceptible to metabolic syndrome than women is unknown. One possibility is the higher frequency of Japanese male subjects (40–70 years old) who had a drinking habit (67%), while that of female subjects was only 25%. In addition, daily fat intake was markedly increased in Japanese subjects (from 9% to 25%), and cholesterol cholelithiasis is one of the most rapidly increasing digestive diseases during the past 50 years. The object of this study is to examine whether a potential sex-related risk factor exists in the manifestation of metabolic syndrome as well as gallstone formation.


  • Sp-family of transcription factors regulates human SHIP2 gene expression

    by Satoru Ishida, Akihiro Funakoshi, Kyoko Miyasaka, Haruo Iguchi, Soichi Takiguchi